<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232257</url>
  </required_header>
  <id_info>
    <org_study_id>H2S-NAC</org_study_id>
    <nct_id>NCT01232257</nct_id>
  </id_info>
  <brief_title>Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)</brief_title>
  <official_title>Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.C. Abrahams</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency
      plays a crucial role in progression of CKD. This leads to endothelial dysfunction,
      hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for
      NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main
      substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in
      humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers
      of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD
      patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after
      treatment with NAC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hydrogen sulfide (H2S)</measure>
    <time_frame>After 48 hours</time_frame>
    <description>Investigate the effect of N-acetylcysteine on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Chronic Kidney Failure</condition>
  <condition>End Stage Kidney Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CKD stage 3-4 (GFR 15-60 ml/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>4 gifts of N-acetylcysteine 600 mg BID</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>CKD patients</arm_group_label>
    <arm_group_label>Hemodialysis patients</arm_group_label>
    <arm_group_label>Peritoneal dialysis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy volunteers:

          -  Adult (&gt; 18 years and older)

          -  Healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine
             dipstick

          -  No medication use

        CKD patient:

          -  Adult (&gt; 18 years and older)

          -  CKD stage 3-4 (GFR 15-60 ml/min)

        Hemodialysis patient:

          -  Adult (&gt; 18 years and older)

          -  Hemodialysis patient

        Peritoneal dialysis patient:

          -  Adult (&gt; 18 years and older)

          -  Peritoneal dialysis patient

        Exclusion criteria:

          -  Unable to give informed consent

          -  Hypersensitivity to N-acetylcysteine

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M C Verhaar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A C Abrahams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>A.C. Abrahams</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Chronic kidney failure</keyword>
  <keyword>End stage kidney disease</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>Hydrogen sulfide</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>Acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Hydrogen Sulfide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

